argenx SE

Stocks

Market Closed - Euronext Bruxelles 11:55:00 2026-08-17 EDT			After hours 12:43:19
855.20 ^EUR	+17.12%		846.40	-1.03%

11:53am	Paris stocks less cautious than their European peers
11:47am	European Stocks Close Lower in Monday Trading Despite Tech, Mining Stocks Rally	MT

Published on 08/17/2026 at 10:20 am EDT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good morning. My name is Leila, and I will be your conference operator today. I would like to welcome everyone to the call. [Operator Instructions]

This article is reserved for our subscribers.

To unlock the article,
subscribe!

Full unlimited browsing across the entire site

Access to all the news and all the data

Access to US, EUROPE AND ASIA Portfolios

Zero Ads for a completely uninterrupted reading experience

Pro Tools: Expert insights, Expert Screeners, historical financial data and reports, thematic lists, transcripts...

11:53am	Paris stocks less cautious than their European peers
11:47am	European Stocks Close Lower in Monday Trading Despite Tech, Mining Stocks Rally	MT
11:17am	European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading	MT
10:43am	Wedbush Adjusts Argenx PT to $1,150 From $1,050, Maintains Outperform Rating	MT
10:20am	Argenx SE - Special Call
09:15am	Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Monday Amid Lower Rate Hike Expectations	MT
07:41am	Argenx drug Vyvgart meets goal in autoimmune myositis study	RE
05:36am	Argenx Announces Positive Topline Results From Phase 3 Alkivia Trial Of Efgartigimod In Autoimmune Myositis	CI
05:10am	Summer holiday lull in Europe
05:08am	Argenx Says Autoimmune Myositis Drug Meets Main Goal in Phase 3 Study	MT
04:45am	Fastned and ArgenX make Benelux shine, SIG Group stirs concern
04:42am	U.S. Futures Mostly Higher as Iran Ceasefire Set to Expire	DJ
04:26am	Argenx Says Autoimmune Myositis Drug Meets Main Goal in Phase 3 Study	MT
04:24am	Argenx Shares Rise After Positive Results From Phase 3 Study of Efgartigimod	DJ
04:11am	Argenx surges after a phase 3 study